AMGEN INC
AMGNNASDAQTrading Snapshot
- Day Range
- $410.56 – $417.67
- 52-Week Range
- $269.77 – $418.40
- Volume
- $6.81B
- Avg Volume
- $5.13B
- Shares Outstanding
- 539.7M
- Next Earnings
- Sep 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $38.67B
- Last Q Revenue
- $9.14B
- P/E Ratio
- 25.4
- P/S Ratio
- 5.8x
- EPS (TTM)
- $16.10
- Dividend Yield
- 2.34%
Why Investors Own AMGN
- ✓High-growth profile — revenue up +17.9% YoY with expanding Biotech exposure.
- ✓Healthy economics — 74% gross margin and 4% free-cash-flow margin.
- ✓Deep pipeline with potential catalysts and durable IP.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AMGEN INC
A company profile for AMGEN INC isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Uncover the latest developments among dow jones stocks in today's session.
Stay informed about the performance of the dow jones index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.65% on an annualized basis producing an average annual return of 14.88%. Currently, Amgen has a market capitalization of $223.91 billion.
What Analysts Really Pressed LLY On This Quarter
Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Recursion Pharmaceuticals, Inc. stock is a Hold: slow revenue, competition, cash burn & dilution risk despite Roche/Sanofi deals. Click for this RXRX update.
Stay informed with the top movers within the dow jones index on Monday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.
Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY
During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]